TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: Although TP53 mutation rate is known to increase with CML disease progression, a 30% reported rate of BC CML cell mutations is markedly lower than the frequency of TP53 mutations reported in solid tumors [33].